Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
ANKK1, ANKRD50, GRK5, PACSIN1 and VPS8 are novel candidate genes associated with late onset Parkinson's disease: Definition of a novel predictive protocol based on polygenic model of inheritance.
Carrillo F et al.
Neurobiology of Disease, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Effect of Clinical and Genetic Factors on the Development of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG) in Egyptian Patients Receiving Beta-Blockers.
El Gindy DMK et al.
Cardiovascular Drugs and Therapy, 2024
Polymorphic Variants in the GRK5 Gene Promoter Are Associated With Diastolic Dysfunction in Coronary Artery Bypass Graft Surgery Patients.
Fassbender P et al.
Anesthesia and Analgesia, 2022
β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery.
Dumeny L et al.
Clinical and Translational Science, 2022
Clinical Implication of Genetic Testing in Dilated Cardiomyopathy.
Lee JH et al.
International Journal of Heart Failure, 2022
Comprehensive Assessment of Indian Variations in the Druggable Kinome Landscape Highlights Distinct Insights at the Sequence, Structure and Pharmacogenomic Stratum.
Panda G et al.
Frontiers in Pharmacology, 2022
The genetics of cardiac failure: Role of a G protein-coupled receptor polymorphism in therapeutic response in an Indian population.
Ramalingam S et al.
Journal of Clinical and Translational Research, 2021
CRISPR/Cas9-mediated generation and analysis of N terminus polymorphic models of β2AR in isogenic hPSC-derived cardiomyocytes.
Kondrashov A et al.
Molecular Therapy. Methods & Clinical Development, 2021
Pharmacogenetic factors affecting β-blocker metabolism and response.
Thomas CD et al.
Expert Opinion on Drug Metabolism & Toxicology, 2020
Influence of GRK5 gene polymorphisms on ritodrine efficacy and adverse drug events in preterm labor treatment.
Chung JE et al.
Scientific Reports, 2020
Adrenergic Polymorphisms and Survival in African Americans With Heart Failure: Results From A-HeFT.
Johnson AE et al.
Journal of Cardiac Failure, 2019
Lack of genetic susceptibility in takotsubo cardiomyopathy: a case-control study.
Mattsson E et al.
Bmc Medical Genetics, 2018
ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure.
Huang J et al.
Cell Discovery, 2018
The influence of two functional genetic variants of GRK5 on tau phosphorylation and their association with Alzheimer's disease risk.
Zhang Y et al.
Oncotarget, 2017
Molecular assembly of rhodopsin with G protein-coupled receptor kinases.
He Y et al.
Cell Research, 2017
The analysis of heterotaxy patients reveals new loss-of-function variants of GRK5.
Lessel D et al.
Scientific Reports, 2016
Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise.
Kohli U et al.
Physiological Genomics, 2015
Pharmacogenomics of hypertension and heart disease.
Arwood MJ et al.
Current Hypertension Reports, 2015
Atomic Structure of GRK5 Reveals Distinct Structural Features Novel for G Protein-coupled Receptor Kinases.
Komolov KE et al.
The Journal of Biological Chemistry, 2015
Categorical complexities of Plasmodium falciparum malaria in individuals is associated with genetic variations in ADORA2A and GRK5 genes.
Gupta H et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, 2015
Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.
Kang S et al.
Journal of Translational Medicine, 2015
Genetics and heart failure: a concise guide for the clinician.
Skrzynia C et al.
Current Cardiology Reviews, 2015
Race, common genetic variation, and therapeutic response disparities in heart failure.
Taylor MR et al.
Jacc. Heart Failure, 2014
Cardiovascular pharmacogenomics: expectations and practical benefits.
Turner RM et al.
Clinical Pharmacology and Therapeutics, 2014
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
Ji Y et al.
The Pharmacogenomics Journal, 2013
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.
Cresci S et al.
Journal of the American College of Cardiology, 2012
The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.
Talameh JA et al.
Journal of Cardiac Failure, 2012
Pharmacogenomics of β-adrenergic receptor physiology and response to β-blockade.
von Homeyer P et al.
Anesthesia and Analgesia, 2011
Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H et al.
Journal of Cardiovascular Pharmacology, 2011
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
Lobmeyer MT et al.
Pharmacogenetics and Genomics, 2011
β(1)-Adrenergic receptor gene polymorphisms and the acute response to atenolol in healthy young Japanese subjects.
Sasaguri T et al.
Journal of Pharmacological Sciences, 2011
RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.
Alves AJ et al.
World Journal of Cardiology, 2010
L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome.
Spinelli L et al.
European Journal of Heart Failure, 2010
GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.
Kurnik D et al.
Pharmacogenomics, 2009
Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.
Dorn GW et al.
Molecular Pharmacology, 2009
Clinical and genetic modifiers of long-term survival in heart failure.
Cresci S et al.
Journal of the American College of Cardiology, 2009
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.
Liggett SB et al.
Nature Medicine, 2008
[Genetic polymorphism in heart failure].
Okamoto H et al.
Nihon Rinsho. Japanese Journal of Clinical Medicine, 2007
Association between gene polymorphism of GRK5 and breast cancer risk in Chinese population.
Wu B et al.
Journal of B.u.on. : Official Journal of the Balkan Union of Oncology, 0